ArticleBMC cancer2025
β-lapachone impairs viability, migration, and epithelial-mesenchymal transition in mammary tumor spheroids.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBreast cancer is the main cancer among women globally and the second most prevalent in Brazil. In the 2023-2025 triennium, it was estimated that nearly 20,000 deaths occurred. The poor prognosis is mainly associated with the occurrence of metastasis. New therapeutic strategies are needed to control the tumor progression and/or improve cancer patients' quality of life. β-lapachone (β-lap) is a natural naphthoquinone obtained from the inner bark of the lapacho trees, native to South America. This compound has several pharmacological properties, including antitumor effects in various solid tumors. Three-dimensional (3D) culture models better replicate the interactions between cells and cells with the extracellular matrix, mimicking tumor structure and behavior. They exhibit in vitro drug responses more similar to in vivo conditions. Given the limited research investigating the anticancer potential of β-lap using 3D cultures, this study aimed to evaluate its effects in breast tumor spheroids.
methodsMCF-7 spheroids were produced through our scaffold-free 3D system. Thereafter, we investigated the cytotoxic and antimetastatic properties of β-lap by analyzing spheroid diameter, cell death, viability, and proteins related to the epithelial-mesenchymal transition (EMT) process (E-cadherin and vimentin).
resultsβ-lap reduced spheroid diameter and induced cell death at 1.2 mg/L after 72 h. The compound decreased viability in a dose-dependent manner: 25% at 1.2 mg/L (after 48 h), 35-45% at 2.5 mg/L, and up to 50% at 5 and 10 mg/L. It further progressively inhibited cell migration and modulated EMT, increasing E-cadherin expression by 18.4% and reducing vimentin by 34.3%.
conclusionsThe natural compound β-lap has the potential to be a promising anticancer agent for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.